BACKGROUND:
Matrix metalloproteinase 9 (MMP-9) is significant in the progression of osteosarcoma (OS) via increasing tumor growth, invasion and metastasis. Although previous reports indicate the prognostic value of MMP-9 in OS, there is still a great degree on inconsistency between studies. Here we report a comprehensive evaluation of the value of MMP-9 in metastasis of OS by conducting a meta-analysis of published studies.

METHODS:
The quantity of the studies was evaluated using the Newcastle-Ottawa quality assessment scale (NOS). Sixteen studies with a total of 816 patients with OS were examined and we calculated the pooled odds ratio (OR) with corresponding 95% confidence interval (CI) (95% CI) to evaluate that the positive expression of MMP-9 predicts neoplasm metastasis and poor survival in OS.

RESULTS:
The results of Meta-analysis indicated that patients with positive expression of MMP-9 were significantly associated with neoplasm metastasis (OR = 4.69, 95% CI: 3.05-7.21, P < .001) and poor survival in OS with the pooled OR of 7.19 (95% CI 4.32-11.98, P < .001) when compared to their counterparts with a negative expression of MMP-9. The results of sensitivity analysis showed that the pooled OR was stable. It doesn't significantly change when a single study was removed.

CONCLUSIONS:
The results of meta-analysis indicated that MMP-9 may be a prognostic biomarker guiding the clinical therapy for OS.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
100% Article relates to my practice (1/1)
0% Article does not relate to my practice (0/1)
0% Undecided (0/1)
2

Will this article lead to more cost-effective healthcare?

100% Yes (1/1)
0% No (0/1)
0% Undecided (0/1)
3

Was this article biased? (commercial or personal)

0% Yes (0/1)
100% No (1/1)
0% Undecided (0/1)
4

What level of evidence do you think this article is?

0% Level 1 (0/1)
0% Level 2 (0/1)
100% Level 3 (1/1)
0% Level 4 (0/1)
0% Level 5 (0/1)